NuCana presented final data from a Phase 2 study at ESMO Congress, showing NUC-7738 combined with Keytruda achieved a 75% disease control rate in metastatic melanoma patients resistant to prior PD-1 inhibitors.
NuCana will discontinue the NuTide:323 study after an initial analysis recommended by the Steering Committee, as the combination treatment was unlikely to achieve superior Progression-Free Survival compared to the control arm.
